U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT07493330) titled 'Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL' on March 19.
Brief Summary: To evaluate the safety and efficacy of Zeprumetostat-based combination therapy, selected according to genotyping results, in patients with primary refractory peripheral T-cell lymphoma (PTCL).
Study Start Date: March 23
Study Type: INTERVENTIONAL
Condition:
PTCL
Refractory
Intervention:
DRUG: Zeprumetostat+Azacitadine
Zeprumetostat: 350 mg bid, orally, till disease progression (PD) or unacceptable toxicity. Azacitadine :100mg D1-D7, subcutaneous injection, should >=2 out of 6 pts experience a DLT, the dose will be adjusted to:...